Fundraising FoxResearch Corporation Technologies
Venture capitalTucson · Seed–Series A · 12 people tracked
Find your way into Research Corporation Technologies
Sign up to see every warm intro you have to Research Corporation Technologies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Research Corporation Technologies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
RCT partners with entrepreneurs, founders, and inventors to translate next-generation life science inventions into commercial products. Through its RCT Ventures program, it provides venture capital to start-up and early-stage companies whose technologies have the potential to become significant biomedical products with a clear competitive edge. The firm also develops and invests in tools that enhance the discovery and manufacture of therapeutics and diagnostics, many of which it makes available to industry via affordable nonexclusive licensing. Its focus spans biotechnology and medical device innovation.
Source: firm website, verified Oct 17, 2026.
Team · 12 people
from the firm's website & public directories
Paul Hoerbelt is Director of Biotechnologies at Research Corporation Technologies. He holds a PhD in neuroscience and neuropharmacology, with over 10 years of experience across life sciences, consulting, and finance, including postdoctoral research at Stanford and management consulting at L.E.K. His background includes venture capital work evaluating biotech companies and co-authoring peer-reviewed research in journals including Nature, Cell, and PNAS.
Brad Morie oversees the licensing of RCT's biotechnology programs, including Pichia Classic, Pichia GlycoSwitch, ClearColi and other protein expression platforms. He previously held business development and licensing roles at Ajinomoto Bio-Pharma Services, Catalent, Lonza, BIOCRATES and Los Alamos National Laboratory.
Souvignier performs scientific and business analysis of early-stage biomedical investment opportunities and manages a portfolio of RCT projects and investments, focusing on life science tools and therapeutics. He has held roles at RCT since 2003, previously worked at Guilford Pharmaceuticals, and holds a Ph.D. in Materials Science and an MBA from the University of Arizona.
Martin serves as CFO, President of Medical Devices, treasurer, and a director of RCT's board, leading the firm's medical device investments. He holds an MBA from UCLA Anderson, an MS in biomedical engineering from USC, and a BS in biology/biochemistry from the University of Michigan.
Wiersma manages RCT's pharmaceutical and biologics patent estate, evaluates IP for investment opportunities, and oversees a portfolio of commercialized technologies. He has been involved in commercializing anticancer agents, radiopharmaceuticals, and the PSA prostate cancer blood test, with focus areas in biologics, diagnostics, oncology, and metabolic disease.
Kirkpatrick has over 25 years of experience managing venture investments and technology development programs across oncology, inflammation, metabolic disease, neurological disorders, and biotherapeutics and life science tools. He oversees RCT's venture investments, technology development, and special licensing programs, and serves on several biomedical startup boards, including as a founding director of the Critical Path Institute.
Founder mafia
2 people who came through Research Corporation Technologies went on to found or lead other companies.
What they invest in
from 11 of 34 portfolio companiesBiotech ×7Healthtech ×3Advanced Manufacturing ×2Deep Tech ×2Hardware ×2Medical Devices ×2Cloud Computing ×1Data & Infrastructure ×1
HQs:United States×10
Investments · 34 tracked
founders shown can be your intro pathBy year:2024 · 12022 · 12019 · 12015 · 12014 · 15 dated
Esperance develops targeted oncology therapeutics designed to selectively kill cancer cells, including chemotherapy-resistant cells, via a proprietary Cationic Lytic Peptide (CLYP) platform, membrane-disrupting peptides, and antibody drug conjugates.
BiotechHealthtechHouston, US
Hector Alila(Executive Officer, Director)Ross Barrett(Director)Peter Hoang(Director)Sonia Deggs(Executive Officer)Carola Leuschner(Executive Officer)
BoardJoseph Lovett(Director)in
Co-investorsLouisiana Funds
Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureBiotechnology Value FundBrandon CapitalForbionLightspeed Venture PartnersTCG Crossover
NP Photonics designs and manufactures fiber-based photonics products, including narrow-linewidth single-frequency fiber lasers, high-power fiber lasers, multi-channel laser systems, fiber amplifiers, injection seeders, mid-infrared fiber sources, and ASE sources.
Advanced ManufacturingDeep TechDefense TechHardwareNew MaterialsTucson, US
Co-investorsShepherd Ventures
Q'Apel Medical designs purpose-built devices for neurovascular and stroke care, developing tools focused on catheter access and navigation through complex vascular pathways.
HardwareHealthtechMedical DevicesFremont, US
R. King Nelson(Executive Officer, Director)inChristopher Martin(Director)J. Avi Roop(Director)Scot Huennekens(Director)
BoardCarter McNabb(Director)
Co-investorsRC CapitalSoleus Capital
S2.dev builds infrastructure services and tools for developers.
Cloud ComputingData & InfrastructureDeveloper ToolsEnterprise SoftwareSan Francisco, US
Shikhar Bhushan(CEO)inStephen Balogh(CTO)inDwarak Govind Parthiban(Founder)inMehul ArorainCristian Caciucin
Co-investorsEight CapitalGrayscale VenturesMaterialized View CapitalOrange CollectivePioneerTranspose Platform Management+11 more
seqWell develops reagents and technologies for next-generation sequencing library preparation, serving academic and institutional research clients.
BiotechDeep TechBeverly, US
Thomas Grant(Executive Officer)inDaniel Calvo(Executive Officer, Director)JoeJackJoseph Mellor(Executive Officer, Director)Joseph Mellor, Ph.D.(Executive Officer, Director)
Co-investorsBroadOak Capital Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AlchemiaAlerion BiomedicalAPT PharmaceuticalsAragen Bioscience, LLCAranaArana Therapeutics, LtdBioCisionBionomicsBioVentures AustraliaCatalyst Biosciences Inc.Coronis Medical Ventures, LLCCryoFluor Therapeutics LLCCylene PharmaceuticalsDisperSol TechnologiesFullerene International CorporationKerberos Proximal Solutions Inc.Lacoste & Romberg ScintrexLeto Medical LLCNP Photonics Inc.OncoGenex TechnologiesParinGenix Inc.S2 GenomicsSertoli Technologies Inc.Spirogen Ltd.Therapeutic Human Polyclonals, Inc.Valeo Medical Inc.Varix Medical Corp.VasoNova, Inc.
Exits · 1
1 acquisitionsAlchemiaacq. by Panther Biotechnology, Inc.
Portfolio news
latest coverage across their companies
s2.dev · economictimes.indiatimes.com · Aug 8, 2026
Frequently asked questions
- How many investments has Research Corporation Technologies made?
- Research Corporation Technologies has 34 tracked investments, 1 of which have exited.
- What stage does Research Corporation Technologies invest at?
- Research Corporation Technologies invests at the Seed, Series A stages.
- What sectors does Research Corporation Technologies focus on?
- Research Corporation Technologies focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
- Where is Research Corporation Technologies located?
- Research Corporation Technologies is headquartered in Tucson, US.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Capricorn Partners is an independent manager of venture capital funds and the listed investment company Quest for Growth, backing innovative companies that use technology as a competitive advantage.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.